Assort Health, a startup building voice AI agents for healthcare, has raised a $120 million Series C led by Menlo Ventures at a $1.2 billion valuation, the company announced on June 24. The round brings Assort's total funding to more than $222 million and ranks among the larger agent-focused deals of the year so far.

From a single scheduling agent to a patient-access platform

Assort began with a narrow claim to fame: it says it built the first voice AI agent to schedule a specialty appointment. That product has since broadened into a platform that spans scheduling, intake forms, referrals, document processing, medication refills, real-time insurance eligibility, lab requests, and payments — the unglamorous administrative layer that sits between a patient and actual care.

The company says its agents have handled more than 190 million patient interactions, drawing on 62,000 care protocols and 1.6 million decision pathways. That accumulated history feeds Synapse, Assort's proprietary model, which the company says learns the patterns of specialty workflows across deployments and then generates the edge cases, tests, and simulations each new clinic has to handle. Assort reports its revenue has grown 20x in the last 15 months.

Why investors are concentrating on healthcare agents

Beyond Menlo Ventures, the round drew Lightspeed Venture Partners, Felicis, First Round Capital, Chemistry, Tau Ventures, Quiet Capital, and former NFL quarterback Joe Montana. Menlo partner JP Sanday will join Assort's board, with partner Matt Murphy serving as a board observer.

The deal fits a clear 2026 pattern: capital is flowing toward "vertical" AI agents that perform a specific, measurable job inside a regulated industry rather than general-purpose assistants. Healthcare operations is one of the most active of those surfaces — front-desk and call-center work is high-volume, rules-heavy, and chronically understaffed, which makes it a natural fit for voice agents that can answer phones around the clock and complete structured tasks.

The caveat in healthcare is the same as it has always been: accuracy and safety are non-negotiable, and a misrouted referral or a botched eligibility check carries real consequences. Assort's pitch is that its proprietary specialty dataset and simulation-heavy testing are what let voice agents operate reliably in that environment. Whether that edge holds as larger platforms and incumbent electronic-health-record vendors push their own agents into the same workflows will be the story to watch over the next year.